StockData

Palisade Bio vs Scholar Rock

PALI and SRRK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PALI and SRRK compare

Scholar Rock is the larger company, worth 31 times as much as Palisade Bio ($5.5B against $176M).

Palisade Bio scores higher on the StockData Score (7 against 2 for Scholar Rock), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPALISRRK
Size and price
Market cap$176M$5.5B
Share price$1.01$45.08
Change, 1 year−52.8%20.5%
Change, 5 years−99.9%67.1%
Beta (5Y)1.150.83
Employees100K289
StockData Score
Total score7 (better)2
Valuation score1 (better)0
Growth score00
Performance score1 (better)0
Health score5 (better)2
Dividend score00
Valuation
P/S352×–
P/B1.4× (better)21.6×
FCF yield–−5.4%
Profitability
Operating margin−7070%–
Net margin−6388%–
Return on equity−51.4% (better)−168%
Financial health
Debt / equity0.000.77 (better)
Interest coverage−4418.6×−38.0× (better)
Current ratio24.26 (better)7.02
Altman Z-score19.21 (better)6.59
Piotroski F-score4 (better)1
Dividends and buybacks
Buyback yield−74.7%−4.6% (better)
Shareholder yield−74.7%−4.6% (better)
Ownership
Held by institutions99.5%114%
Held by insiders4.7%28.9%
Insider net buying, 12 months−$124K (better)−$7.4M
Short interest, % of float17.6%27.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.